Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/12/22 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/12/22 | DEF 14A | Definitive proxy statements |
|
23 | |
| 04/11/22 | 8-K | Current report filing |
|
   |
3 |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/08/22 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
